Table 2.
Type of vaccine and antibody measurement in CKD and HD patients, and KTR. Continuous data is displayed as median, 25%, and 75% percentiles. Numeric data is displayed as number of participants (n) and percentage (%) where appropriate (sums do not add up to 100% due to rounding).
| CKD (n = 160) | HD (n = 206) | KTR (n = 216) | |
|---|---|---|---|
| Type of antibody measurement (n, %) | |||
| Abbott SARS-CoV-2 IgG II Quant Assay | 65 (40.6) | 84 (40.8) | 88 (40.7) |
| Liaison® SARS-CoV-2 S1/S2 IgG | 95 (59.4) | 122 (59.2) | 128 (59.3) |
| Vaccine (n, %) | |||
| BNT162b2 | 93 (58.1) | 198 (96.1) | 106 (49.1) |
| mRNA-1273 | 67 (41.9) | 8 (3.9) | 110 (50.9) |
| Results of antibody measurement | |||
| Abbott SARS-CoV-2 IgG II Quant Assay titer (BAU/mL) |
230.3 (48.3–497.6) | 151.6 (47.7–458.4) | 4.75 (3.0–30.2) |
| Liaison® SARS-CoV-2 S1/S2 IgG titer (AU/mL) | 602.0 (252.5–800.0) | 121.5 (32.0–293.0) | 10.3 (1.9–74.3) |
| Non-response (n, %) | 20 (12.5) | 25 (12.1) | 108 (50.0) |
| Time between 1st vaccination and AB measurement (days) | 91 (90–96) | 91 (88–94) | 91 (90–95) |